Infectious Disease vs Oncology — Deal Terms Comparison

Infectious Disease Median Upfront

$604M

Total: $2.3B

Oncology Median Upfront

$258M

Total: $1.6B

Infectious Disease Royalties

8.1%-16.3%

Tiered to 20.3%

Oncology Royalties

11.8%-19.3%

Tiered to 23.3%

Model Your Deal

Market Analysis

Infectious Disease and Oncology represent distinct licensing landscapes with different risk-reward dynamics. Phase 2 infectious disease deals carry a median total deal value of $2.3B with $604M upfront, compared to $1.6B total value and $258M upfront for oncology. The differences reflect divergent clinical development timelines, regulatory pathways, and addressable market sizes.

Deal structures differ across therapeutic areas. Infectious Disease deals allocate 26% to upfront and 74% to milestones, while Oncology deals split 16%/84%. Development milestones are $376M for infectious disease versus $345M for oncology, reflecting the different clinical trial designs and approval standards in each area.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How do infectious disease and oncology deal terms compare?

Infectious Disease Phase 2 deals average $2.3B total value ($604M upfront), while Oncology deals average $1.6B ($258M upfront). The differences are driven by addressable market size, clinical development complexity, and regulatory pathway characteristics.

Which therapeutic area commands higher royalty rates: Infectious Disease or Oncology?

Infectious Disease base royalties range from 8.1% to 16.3%, while Oncology royalties range from 11.8% to 19.3%. Royalty rates reflect pricing power, competitive dynamics, and patent protection characteristics specific to each therapeutic area.

What drives the deal value differences between infectious disease and oncology?

Key factors include addressable patient population size, clinical trial costs and timelines, regulatory pathway complexity, pricing and reimbursement dynamics, and competitive landscape density. Infectious Disease and Oncology each have unique value drivers that shape deal economics.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included